Procarbazine
- Generic Name
- Procarbazine
- Brand Names
- Matulane
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N3O
- CAS Number
- 671-16-9
- Unique Ingredient Identifier
- 35S93Y190K
- Background
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
- Indication
For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
- Associated Conditions
- Non-Hodgkin's Lymphoma (NHL), Oligodendroglioma, Primary Central Nervous System Lymphoma, Stage III Hodgkin's Disease, Stage IV Hodgkin's Disease
- Associated Therapies
- -
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT05008224
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-05-01
- Target Recruit Count
- 208
- Registration Number
- NCT03495960
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇮🇹Ospedale C.e G. Mazzoni, Ascoli Piceno, Italy
Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 92
- Registration Number
- NCT02800447
HD21 for Advanced Stages
- Conditions
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1500
- Registration Number
- NCT02661503
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
- Conditions
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 109
- Registration Number
- NCT02315326
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 40
- Registration Number
- NCT02298283
- Locations
- 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷Hôpital André Mignot, Le Chesnay, France
🇫🇷Centre Léon Bérard, Lyon, France
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 100
- Registration Number
- NCT01569204
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
Prospective Study on HIV-related Hodgkin Lymphoma
- Conditions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Harlachinger Krebshilfe e.V.
- Target Recruit Count
- 130
- Registration Number
- NCT01468740
- Locations
- 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪Ärzteforum Seestrasse, Berlin, Germany
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 91
- Registration Number
- NCT01399372
- Locations
- 🇺🇸
Fresno Cancer Center, Fresno, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.